Publications by authors named "Deborah Hurst"

Claim this Profile
D
Diagnosis and treatment of coagulopathy using thromboelastography with platelet mapping is associated with decreased risk of pulmonary failure in COVID-19 patients.
Tjasa Hranjec, Mackenzie Mayhew, Bradley Rogers, Rachele Solomon, Deborah Hurst

Blood Coagul Fibrinolysis· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integral Use of Thromboelastography With Platelet Mapping to Guide Appropriate Treatment, Avoid Complications, and Improve Survival of Patients With Coronavirus Disease 2019-Related Coagulopathy.
Tjasa Hranjec, Michael Estreicher, Bradley Rogers, Lisa Kohler, Rachele Solomon, Deborah Hurst

Crit Care Explor· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia.
Thomas J Kipps, Herbert Eradat, Sebastian Grosicki, John Catalano, Walter Cosolo, Deborah Hurst

Leuk Lymphoma· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States.
Bruno C Medeiros, Sacha Satram-Hoang, Deborah Hurst, Khang Q Hoang, Faiyaz Momin

Ann Hematol· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III safety study of rituximab administered as a 90-minute infusion in patients with previously untreated diffuse large B-cell and follicular lymphoma.
Shaker Dakhil, Robert Hermann, Marshall T Schreeder, Stephanie A Gregory, Marc Monte, Deborah Hurst

Leuk Lymphoma· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma.
Khuda D Khan, Christos Emmanouilides, Don M Benson, Deborah Hurst, Pablo Garcia

Clin Cancer Res· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response.
William Larry Gluck, Deborah Hurst, Alan Yuen, Alexandra M Levine, Mark A Dayton

Clin Cancer Res· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion.
Jerry S Powell, Margaret V Ragni, Gilbert C White, Jeanne M Lusher, Carol Hillman-Wiseman, Deborah Hurst

Blood· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis